Heart failure & cardiomyopathiesSecondary analysis
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM
- Secondary analysis of the ACACIA-HCM randomised trial
- responder analysis
Authors' conclusion
In patients with nHCM, aficamten was associated with improvements across a broad range of clinically relevant measures including symptom burden and diastolic function.
Study context
- Population
- Patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM)
- Participants
- 258 vs 259
- Comparison
- Aficamten vs placebo
- Aficamtenn = 258
- Placebon = 259reference
- Primary endpoint
- Overall clinical response by number of favorable outcomes (symptom burden, exercise capacity, LA volume index, septal e', NT-proBNP): nonresponder (none), limited (1 or 2), partial (3 or 4), complete (all 5)
- Follow-up
- Week 36
Primary result
As reported in the abstract
Partial or complete clinical response (≥3 outcomes) · 36 weeks
P < 0.001
Further findings
Improvement in individual measures · 36 weeks
Symptom burden
Peak exercise capacity
LA volume index
Septal e'
NT-proBNP
- Improvement in individual measures — P<0.05 for all except peak oxygen uptake
- P=0.1
Improvement in individual measures · 36 weeks
- NNT ranged from 1.7 (NT-proBNP reduction) to 14 (peak oxygen uptake improvement)
Original publication
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM. Circulation. Published 28 August 2026. doi:10.1161/circulationaha.126.082026
Summarised from the published abstract; every number is checked against it